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Methods From January 2012 to December 2013, patients who underwent
RFA of cavotricuspid isthmus for typical atrial flutter in our centre were
retrospectively included.
Results Of 166 patients (137 men, mean age: 66.7±10 years), 61 (36.7%)
had a history of AF. 
The mean CHA2DS2VASc and HASBLED scores were 2.49 and 1.11. 
Mean left ventricular ejection fraction was 53±13% and 77 (46.4%)
patients had a subsequent cardiomyopathy, whereas 61 (36.7%) had a history
of AF. Of 166 RFA, sinus rhythm was obtain in 160 patients and 141 (84.9%)
procedures were considered as a complete success (complete isthmus block).
During a mean follow up of 489±244 days, there were 7 (5%) and 9 (36%)
AFL recurrence in patients with and without isthmus block respectively. New-
onset or recurrent AF were experienced by 63 (39%) patients. 
History of AF was an independent predictive factor of AF (33 (52.4%) vs.
28 (27.2%) patients; p=0.002). 
The younger patients (64.4 ±11.7 vs. 68.2±9.9 years; p=0.03) and patients
with lower CHA2DS2VASc score had more AF post ablation (2.16±1.53 vs.
2.70±1.57; p=0.03).
Conclusion After successful RF ablation, AF was frequent in patients
especially in patient with AF history before AFL RFA, but also occurred in
patient with lone AFL. Age and CHA2DS2VASc score were inversely associ-
ated with onset of AF. Identify AF and risk patients is crucial regarding to
long-term antithrombotic therapy.
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Goal to evaluate routine anesthesia strategy in ablation procedures by
French electrophysiologists (EPs). 
Method A questionnaire was e-mailed to 110 French EP. 
Results Answers were obtained from 95 EP (86.4%): 25% working in a
private center, 75% in a public center. Anesthesiologists are always available
in 70.8% of private centers vs 11.4% of public centers. When available, 54.2%
are entirely dedicated to electrophysiology in private vs 18.6% in public cen-
ters. When an anesthesiologist is not available, sedation is obtained using mid-
azolam associated with nalbuphin (32%), morphine (16%) or fentanyl (9%).
Propofol is used occasionally by 29% of EPs (35% in public, 9% in private
centers). Nitrous oxide inhalation gas is available in 40% of private and 34.3%
of public centers. Private EPs are satisfied with the anesthesiologist strategy in
100% of cases versus only 41% of public EP. A good or very good relation-
ship with anesthesiologists is declared by 92% of private EPs versus only 56%
of public EPs. 
Conclusions Collaboration of anesthesiologists with EPs seems to be
more operational in private centers. Deep sedation seems to be used as an
alternative when anesthesiologists are not available more often in public
centers. 
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Background Current ESC guidelines require anticoagulation with VKA in
patients with “valvular atrial fibrillation (AF)”, which includes all types of
prosthetic valve. We evaluated the value of the CHA2DS2 -VASc score for
thromboembolism risk assessment in AF patients with biological valve
replacement.
Methods and results Among 8962 patients with AF seen between 2000
and 2010, 8053 (90%) had "non-valvular AF” and 909 (10%) had valvular
AF. Patients with valvular AF had a biological prosthesis in 59% (n=549),
among which 77% (n=426) had a single aortic prosthesis and 64% (n=309)
received a VKA. Patients with aortic bioprosthesis were older and had a
higher CHA2DS2-VASc score than those with a mitral prosthesis or a
double valve replacement. During a follow up of 876±1048 days, 681
stroke/thromboembolic events were recorded. The occurrence of events
were similar in patients with bioprosthesis compared to the patients
without prosthesis: (hazard ratio HR 1.10, 95% CI 0.83-1.45, p=0.52).
Patients with aortic bioprosthesis tended to have a higher risk of embolic
events vs other AF patients with bioprosthesis (HR 1.73, 95% CI 0.87-
3.45), p=0.12). In multivariate analysis, older age and higher CHA2DS2-
VASC score were the only predictors of embolic events whilst the
presence of a bioprosthesis was not an independent predictor of events.
The CHA2DS2-VASC score predicted the embolism risk in AF patients
with a bioprosthesis (c-statistic 0.55 95% CI 0.47-0.63) but was less
efficient than in “non-valvular” AF patient (c-statistic 0.66, 95% CI 0.64-
0.67). 
Conclusion This “real world” results support the use of oral anti-
coagulation in AF patients who have bioprosthetic heart valves. It also
supports the use of CHA2DS2-VASc scoring for the risk evaluation of AF
patients with bioprostheses, albeit with reduced reliability. Patients with
aortic bioprosthesis had a non significant higher risk of embolic events. A
higher CHA2DS2-VASc score in these patients is likely to explain these
results.
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Abstract 0362 – Table: predictive factors of AF
No FA post ablation 
(N=103)
FA post ablation 
(N=63) 
p
Men/Women (N/N) 89/14 48/15 0.09
Age (years) 68.2+/–9.9 64.4+/–11.7 0.03*
SAS 10 (9.7) 4 (6.3) 0.57
Cardiopathy 53 (51.5) 24 (38.1) 0.11
History of AF (N [%]) 28 (27.2) 33 (52.4) 0.002*
Dilated LA (N [%]) 43 (41.7) 32 (50.8) 0.4
Dilated LV (N [%]) 12 (11.7) 12 (19) 0.41
LVEF <45% (N [%]) 29 (28.2) 10 (15.9) 0.09
High blood pressure 
(N [%]) 63 (61.2) 31 (49.2) 0.14
Age ≥75 years 29 (28.2) 15 (23.8) 0.59
Diabetes mellitus 18 (17.5) 9 (14.3) 0.66
CHA2DS2VASc 2.7+/–1.57 2.16+/–1.53 0.03*
BMI (kg/m2) 27.4+/–5.5 27.9+/–4.9 0.55
Creatinine clearance 
(Cockroft) 78.1+/–30.8 85.3+/–37.4 0.19
Creatinine clearance 
(MDRD) 72.8+/–22.4 73.9+/–23.7 0.76
SAS: sleep apnoea syndrome; AF: atrial fibrillation; LA: left atrial; LV: left 
ventricular
LVEF: left ventricular ejection fraction; BMI: body mass index
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